Zai Lab has launched its electric fields treatment for glioblastoma multiforme (GBM) in Hong Kong. In September, Zai acquired greater China rights to Novocure’s Optune, paying $15 million upfront plus sales milestones. Optune is not yet approved for mainland China use. The product uses electric fields tuned to specific frequencies to disrupt cell division, inhibiting tumor growth and causing the death of affected cancer cells. Zai’s in-licensed PARP inhibitor is also available in Hong Kong.
Source: China Biotoday
